tbuckley/cabot-search huggingface dataset:
A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
Authors: I. Miller, C.D. Lynggaard, S. Lophaven, C. Zachariae, D.N. Dufour, G.B.E. Jemec
Journal: British Journal of Dermatology (2011)

Journal Article A double‐blind placebo‐controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa Get access I. Miller, I. Miller Department of Dermatology, Roskilde Hospital, Health Sciences Faculty, University of Copenhagen, Roskilde 4000, Denmark Iben Miller. E‐mail: miller@dadlnet.dk Search for other works by this author on: Oxford Academic Google Scholar C.D. Lynggaard, C.D. Lynggaard Department of Dermatology, Roskilde Hospital, Health Sciences Faculty, University of Copenhagen, Roskilde 4000, Denmark Search for other works by this author on: Oxford Academic Google Scholar S. Lophaven, S. Lophaven Department of Dermatology, Roskilde Hospital, Health Sciences Faculty, University of Copenhagen, Roskilde 4000, Denmark Search for other works by this author on: Oxford Academic Google Scholar C. Zachariae, C. Zachariae Department of Dermatology, Gentofte Hospital, Copenhagen, Denmark Search for other works by this author on: Oxford Academic Google Scholar D.N. Dufour, D.N. Dufour Department of Dermatology, Roskilde Hospital, Health Sciences Faculty, University of Copenhagen, Roskilde 4000, Denmark Search for other works by this author on: Oxford Academic Google Scholar G.B.E. Jemec G.B.E. Jemec Department of Dermatology, Roskilde Hospital, Health Sciences Faculty, University of Copenhagen, Roskilde 4000, Denmark Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 165, Issue 2, 1 August 2011, Pages 391–398, https://doi.org/10.1111/j.1365-2133.2011.10339.x Published: 01 August 2011
Coronary plaque distribution and endothelial dysfunction in younger obstructive sleep apnea patients
Authors: Heleen Vrints, Bharati Shivalkar, Katrien Kluppels, Olivier M. Vanderveken, Evert Hamans, Paul Van de Heyning, Wilfried De Backer, Christiaan Vrints, Johan Verbraecken
Journal: European Respiratory Journal (2011)

Background: Obstructive sleep apnea (OSA) occurs mainly in middle aged subjects and is associated with a higher incidence of cardiovascular complications.

Aim: Assessment of subclinical cardiovascular risk factors in asymptomatic younger OSA patients.

Methods: Patients undergoing a full polysomnography and with an apnea hypopnea index (AHI) >20, were included. They underwent an echocardiography, a measurement of the carotid intima media thickness (IMT), analysis of the endothelial function (brachial flow mediated dilatation, FMD) and a Multislice Computed Tomography (CT) for determination of the coronary plaque burden. We assessed 13 coronary segments for degree of stenosis (1: normal; 2:  70% stenosis).

Results: The patients [n=91; age=50±10y, M/F 79/12] had severe OSA, mean AHI of 52±23, and 59% had up to eleven coronary segments showing a variable degree of plaque burden. There was a significant correlation between the number of affected coronary segments and IMT (r=0.451; p<0.001), FMD (r=-0.255; p=0.019), coronary arterial calcium score (r=0.546;p<0.001), interventricular septum thickness (r=0.217;p=0.041) and age (r=0.414;p<0.01). Correlations were maintained after adjustment for hypertension, age and smoking. Patients with coronary plaques were older (54±9y versus 47±9y; p<0.01), had thicker IMT (680±127μm versus 587±89μm; p<0.01) and had abnormal FMD (6.1±2.1% versus 7.3±2.5%; p=0.029).

Discussion: Our results suggest occurrence of significant subclinical coronary abnormalities and endothelial dysfunction in asymptomatic younger severe OSA patients. Routine screening for subclinical cardiovascular risk factors in OSA may be beneficial.
Where We Draw the Line
Authors: Jerome W. Freeman
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 18655: Efficacy of Cardiac Computerized Tomographic Angiography in the Evaluation of Patients with Cocaine-Induced Chest Pain: A Pilot Randomized Trial
Authors: Richard Peralta, Andrew Yoon, Moustapha Atoui, Karomibal Mejia, Maryam Afshar, James Min, Jonathan N. Bella
Journal: Circulation (2014)

Background: Cocaine-induced chest pain (CICP) is reported in 40% of patients using cocaine and is associated with frequent emergency room visits and hospital admissions. Hypothesis: Coronary computed tomographic angiography (CCTA) has better outcomes than standard-of-care (SOC) for the evaluation of patients with CICP. Method: CICP patients were randomized to CCTA protocol or SOC. The primary outcome of the study was a composite of recurrent emergency room visits and hospital admissions. Secondary outcomes included length of stay, major adverse cardiovascular events and all-cause mortality. Results: The study population consisted of 202 patients with CICP (CCTA=23 and SOC=179). As compared to SOC, the number of emergency room visits in the CCTA group were lower at 30 days (1.04±0.1 vs. 1.24±0.5, p=0.012) and 1 year (2.43±0.9 vs. 2.61±2.1, p=0.008), but not at 3 years (5.04±3.3 vs. 4.87±1, p=0.112) findings that were independent of CCTA results. Mean admission rates for the CCTA group were slightly but not significantly lower than the SOC group at 30 days (0.91±0.1 vs.1.10±0.2 p=0.438) and 1 year (1.52±0.3 vs. 1.82±0.3 p=0.187), but not at 3 years (3.22±0.6 vs. 2.95±0.5, p=0.111). Hospital length of stay was also lower in CCTA patients than in SOC patients (2.61±0.5 vs. 3.34 ± 0.5 p&lt;0.001). After 3 year follow-up, there was 1 major adverse cardiovascular event in the CCTA group compared to 22 in the SOC group (p=0.024). No patient died in the CCTA while 3 patients died from any cause in the SOC group (p=0.776) after 3 years of follow-up. Conclusion: In this prospective randomized trial, CCTA reduced near and intermediate-term but not long-term rates of emergency room visits and hospitalizations. When compared to SOC, the use of CCTA was associated with a reduction of major adverse cardiovascular events. Larger randomized controlled trials to further assess the efficacy of a CCTA-based strategy for CICP appear warranted.
Silica-induced inflammasome activation in vitro and in rat lungs
Authors: Paul Peeters, Niki Reynaert, Irene Eurlings, Timothy Perkins, Brooke Mossman, Roel Schins, Emiel Wouters, Catrin Albrecht
Journal: European Respiratory Journal (2013)

Rationale: Impingement of toxic mineral particles in the lung can cause sustained inflammation and silicosis. In this study we intended to demonstrate crystalline silica-induced inflammasome activation and the effect on fibroblast proliferation in vitro and in rat lung tissue in vivo with dependency to particle surface reactivity.

Methods: siRNA mediated knock down in BEAS-2B and THP-1 cells was performed followed by 24h exposure to silica with or without surface modifications. We screened for IL-1β, bFGF and HMGB1 with ELISA. Conditioned media was added to fibroblasts. Wistar rats were instilled with PBS, 2mg Dorentruper quartz (DQ12) or 2mg polyvinylpyridine-N-oxide (PVNO) coated quartz. At days 3, 7, 28, 90, 180 and 360 after instillation, inflammasome activation was measured using immunohistochemistry.

Results: We detected inflammasome dependent release of IL-1β, bFGF and HMGB1 following cristobalite and quartz treatment in vitro . Conditioned medium from BEAS-2B cells had significant impact on fibroblast proliferation. In quartz treated rats, acute inflammation was observed at 3 and 7 days. Semi-quantitative analysis revealed increased matrix deposition and fibrosis at 90, 180 and 360 days. Silicotic nodules were localized in silica exposed groups at 180 and 360 days. Levels of caspase-1 activation and IL-1β were increased in quartz versus vehicle exposed rats. PVNO-coated quartz reduced the grade of leukocyte influx and the level of NLRP3 activation.

Conclusion: Our novel data indicate NLRP3 inflammasome activation by crystalline silica polymorphs in cell culture systems and in the lungs of quartz exposed rats in association with the crystalline surface reactivity.
Estrogen Plus Progestin and Risk of Venous Thrombosis
Authors: Pierre-Yves Scarabin, Emmanuel Oger, Tabassome Simon, Geneviève Plu-Bureau
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 187: Changes in High-Density Lipoprotein Cholesterol and Complement C3 are Strongly Inversely Correlated in the Setting of Niacin Therapy in Humans
Authors: Richard L Dunbar, Ramprasad Gadi, LeAnne Bloedon, Megan L Wolfe, Amanda L Baer, Daniel J Rader, Frederick F Samaha
Journal: Circulation (2007)
Discrepancy between echocardiographic and patient‐reported health status response to cardiac resynchronization therapy: results of the <scp>PSYHEART‐CRT</scp> study
Authors: Henneke Versteeg, Jetske van 't Sant, Maarten J. Cramer, Pieter A. Doevendans, Susanne S. Pedersen, Mathias Meine
Journal: European Journal of Heart Failure (2013)
Effects of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Myelosuppression induced by Multiple Cycles of High-Dose Chemotherapy in Patients With Advanced Breast Cancer
Authors: Klaas Hoekman, John Wagstaff, Cees J. van Groeoningen, Jan B. Vermorken, Epie Boven, Herbert M. Pinedo
Journal: JNCI Journal of the National Cancer Institute (1991)

In this study, 18 patients with advanced breast cancer were treated with multiple cycles of doxorubicin (75 or 90 mg/m 2 ) plus cyclophosphamide (750 or 1000 mg/m 2 ) every 21 days. Granulocyte-macrophage colony-stimulating factor (GM-CSF) (250 ng/m 2 per day) was administered by continuous infusion during 10 days (days 2–12), starting in the first or second cycle of chemotherapy. Sixteen (89%) of 18 patients (95% confidence interval, 65%–99%) achieved an objective remission, five (28%) of which were complete. The median duration of response was 7 months. When GM-CSF was used for the first time, it had an effect on the kinetics of all blood cells, including neutrophils, lymphocytes, throm-bocytes, and reticulocytes. However, in subsequent cycles of chemotherapy, the stimulatory effect of GM-CSF on hematopoiesis was substantially diminished. World Health Organization grade 3 and 4 neutropenia and thrombo-cytopenia necessitated dose reductions of doxorubicin and cyclophosphamide from cycle 2 onward in all patients treated with the highest dose. Side effects of GM-CSF included fever, general weakness, and hypotension. These toxic effects mimicked sepsis, and hospital admission for treatment with intravenous antibiotics was required for 73 days in 61 cycles of chemotherapy that included GM-CSF. Dose-intensive chemotherapy produced a high response rate in patients with advanced breast cancer. However, GM-CSF administered from day 2 to day 12 at a dose of 250 (ig/m 2 ) per day by continuous infusion did not adequately ameliorate the myelosuppression induced by repeated cycles of dose-intensive chemotherapy. [J Natl Cancer Inst 83:1546–1553,1991]
Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes
Journal: Diabetes Care (2009)

OBJECTIVE To evaluate long-term effects of continuous glucose monitoring (CGM) in intensively treated adults with type 1 diabetes. RESEARCH DESIGN AND METHODS We studied 83 of 86 individuals ≥25 years of age with type 1 diabetes who used CGM as part of a 6-month randomized clinical trial in a subsequent 6-month extension study. RESULTS After 12 months, median CGM use was 6.8 days per week. Mean change in A1C level from baseline to 12 months was −0.4 ± 0.6% (P &amp;lt; 0.001) in subjects with baseline A1C ≥7.0%. A1C remained stable at 6.4% in those with baseline A1C &amp;lt;7.0%. The incidence rate of severe hypoglycemia was 21.8 and 7.1 events per 100 person-years in the first and last 6 months, respectively. Time per day with glucose levels in the range of 71–180 mg/dl increased significantly (P = 0.02) from baseline to 12 months. CONCLUSIONS In intensively treated adults with type 1 diabetes, CGM use and benefit can be sustained for 12 months.
Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency
Authors: Zuguo Liu, Stephen C Pflugfelder
Journal: Ophthalmology (1999)

Purpose To evaluate corneal surface regularity and the effect of artificial tears on the regularity of the corneal surface in dry eye. Design A prospective, clinic-based, case-control study. Participants A total of 64 eyes of 33 normal subjects and 42 eyes of 22 patients with aqueous tear deficiency were evaluated. Methods Indices of the TMS-1 corneal topography instrument (Tomey Technology, Cambridge, MA) were used to evaluate corneal surface regularity and potential visual acuity (PVA) in patients with aqueous tear deficiency dry eye before and after the instillation of artificial tears and in normal subjects. The TMS-1 topographic maps were classified into round, oval, symmetric bow-tie, asymmetric bow-tie, and irregular patterns. Main outcome measures The surface regularity index (SRI), surface asymmetry index (SAI), PVA index, and topographic pattern of the TMS-1 were compared between normal and dry eyes and in dry eyes before and after the instillation of artificial tears. Results The SRI and SAI were significantly elevated and the PVA was significantly reduced in dry eye patients compared with normal subjects: 0.31 ± 0.22, 0.30 ± 0.16, and 20/17.89 ± 20/3.04, respectively, in normal subjects and 1.28 ± 0.73, 1.05 ± 1.17, and 20/33.45 ± 20/13.99, respectively, in patients with dry eye (P < 0.001 for all indices). The average amount of astigmatism was also increased in dry eyes (2.10 ± 1.96 prism diopters) compared with normal eyes (1.13 ± 0.53 prism diopters, P = 0.02). In dry eyes, the SRI and SAI were positively correlated with corneal fluorescein staining scores (P = 0.005 for SRI and P = 0.016 for SAI). The mean PVA was not significantly different from the mean actual corrected visual acuity. The dry eyes had a significantly lower percentage of symmetric bow-tie patterns and a greater percentage of irregular patterns on topographic maps than normal eyes. After the instillation of artificial tears, the SRI, SAI, and mean astigmatism all decreased significantly (P < 0.001 for SRI, P < 0.002 for SAI, P = 0.04 for astigmatism) and the PVA improved (P < 0.001) in dry eyes. An irregular topographic pattern was observed in 45.24% of dry eyes, and this decreased to 30.95% after the instillation of artificial tears (P < 0.005). Conclusions Patients with aqueous deficiency have an irregular corneal surface that may contribute to their visual difficulties. The SRI and SAI could be used as objective diagnostic indices for dry eye as well as for evaluating the severity of this disease and the effect of artificial tears. Artificial tears have the secondary benefit of smoothing the corneal surface in dry eye.
Estrogen Replacement Therapy and Risk of Ovarian Cancer in Postmenopausal WomenDifferences in Success Rates of Noninvasive VentilationSpirituality and Chronic IllnessPrematurity and Later Cognitive OutcomesAspiration of a Dental Appliance in a Patient With Alzheimer Disease
Authors: Kenneth Burry, Joanna M. Cain
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3711: Erk inhibition as a therapeutic option for the treatment of Raf- and Mek- inhibitor resistant tumors
Authors: Irene Seipelt, Peter Schmidt, Helene Maerzhaeuser, Matthias Gerlach, Kai Jung, Tilmann Schuster, Michael Teifel
Journal: Cancer Research (2014)

Abstract The MAPK pathway represents a prime target for therapeutic intervention in cancer. Recent approvals of B-Raf and Mek inhibitors lead to exciting antitumor activities and survival benefits. However the observation of resistance to such Raf and Mek inhibitors has been documented in both clinical and preclinical trials. These phenomena stimulated further research into the regulation of the MAPK pathway and led to the suggestion to target the downstream kinase Erk, as well as to combine its targeting with Raf and Mek inhibitors. Here we report that Erk inhibitors result in efficient growth inhibition of tumor cells that are resistant to Raf and Mek inhibitors. AEZS-134 - a highly potent and selective ATP competitive Erk inhibitor - overcomes the Raf inhibitor induced paradoxical cell activation and the aquired resistance to Mek inhibitors in tumor cells. We demonstrate potent antiproliferative activity of AEZS-134 in B-Raf wildtype, B-RafV600E mutant, Ras wildtype and K-Ras mutant tumor cell lines in comparison to common Raf inhibitors. Furthermore we show that AEZS-134 is efficacious in Mek inhibitor resistant Hct116 and MDA MB231 cells which have been well characterized in terms of Mek F129L allosteric binding pocket mutation, varying degrees of K-Ras amplification, cellular proliferation assays and MAPK pathway phosphorylation studies. Our data provide a rational for new therapeutic opportunities by using Erk inhibitors in oncology. In order to maximize therapeutic benefit for patients and considering that Erk is directly downstream of B-Raf and Mek, targeting Erk may be more effective than targeting Raf or Mek in a variety of MAPK resistance settings. AEZS-134 and related compounds provide potent and selective tools to help address this question. Development of the Erk inhibitors by Æterna Zentaris is integral part of our inhouse kinase research program comprising the investigation of different compounds for single Erk inhibition, single PI3K inhibition and dual kinase inhibitions of Erk and PI3K. All compounds are exclusively synthesized by our medicinal chemistry department. Citation Format: Irene Seipelt, Peter Schmidt, Helene Maerzhaeuser, Matthias Gerlach, Kai Jung, Tilmann Schuster, Michael Teifel. Erk inhibition as a therapeutic option for the treatment of Raf- and Mek- inhibitor resistant tumors. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3711. doi:10.1158/1538-7445.AM2014-3711
Abstract 20707: Macrophage Mitochondrial Fission is Essential for Continued Clearance of Apoptotic Cells and Plays a Protective Role in Advanced Atherosclerosis
Authors: Ying Wang, Ira Tabas, Masatoshi Nomura
Journal: Circulation (2014)

Introduction: The mitochondrial dynamic processes of fission and fusion influence and integrate with multiple physiologic and pathophysiologic processes. Mitochondrial dynamics dysregulation has been implicated in atherosclerosis, but little is known about the role of myeloid cell specific mitochondrial dynamics in the progression of atherosclerosis. In macrophage-enriched murine atherosclerosis lesion areas, we have found that levels of mitochondrial fission protein DRP1 down-regulated as the lesion progresses. In contrast, the mitochondrial fusion protein MFN2 is up-regulated. Further, mitochondria in lesional macrophages show hyperfusion morphology as the lesion develops. These suggest that mitochondria in macrophages undergo hyperfusion during the lesion progression. Hypothesis: We hypothesize that mitochondrial hyperfusion plays a significant role in atherosclerosis. Methods: We used a model Drp1fl/fl LysmCre+/-Ldlr-/-mice who have hyperfused mitochondria in Mϕs to test the functional significance of mitochondrial hyperfusion in atherosclerosis. Results: We have found that inhibition of Mϕ mitochondrial fission leads to a striking increase of necrotic core area and the accumulation of apoptotic cells, which are likely due to the defective phagocytic clearance of apoptotic cells (efferocytosis) in the advanced stage of atherosclerosis in vivo. This is further verified by another in vivo efferocytosis assay: Drp1fl/fl LysmCre+/-mice are defective of clearing apoptotic thymocytes in vivo. Mechanistically, the continued uptake of apoptotic cellsis impaired in Mϕs with hyperfused mitochondria. This is because of the lower level of uncoupling protein 2 (UCP2), the mitochondrial inner membrane protein that prevents the sustained elevation of inner membrane potential (Δψ). Chemical uncoupler FCCP or restoration of UCP2 can correct the efferocytosis deficiency in DRP1 knockout Mϕs. Conclusions: Macrophage mitochondrial fission is essential for continued clearance of apoptotic cells and plays a protective role in advanced atherosclerosis. This study indicates that mitochondrial fusion/fission could be a novel therapeutic target to prevent lesion necrosis and stabilize the advanced plaques in humans.